CSL Behring, the biopharmaceutical company behind the hemophilia B gene therapy HEMGENIX ® (etranacogene dezaparvovec-drlb), announced on March 17, 2026, a temporary global stockout of the therapy. This disruption means that some individuals in countries where HEMGENIX is commercially available may experience delays in accessing treatment.

The National Bleeding Disorders Foundation (NBDF), a leading nonprofit supporting people with bleeding disorders, is proud to congratulate Matthew Delaney, government relations manager, on being named to City & State New York’s 2026 Albany 40 Under 40, an annual list recognizing rising stars in New York State government, politics, and public service.

A Personal Connection to the Bleeding Disorders Community

Federal:  

NBDF Wraps Up Another Successful Washington Days

The National Bleeding Disorders Foundation (NBDF) is pleased to announce a new matching grant partnership with Save One Life that will double the community’s impact for children living with bleeding disorders, including hemophilia A, hemophilia B, and von Willebrand disease in developing countries.

Pathway to Cures (P2C), the venture philanthropy fund of the National Bleeding Disorders Foundation (NBDF), is pleased to announce the appointment of Michael Recht, MD, PhD, MBA, as chief medical and scientific advisor.

BioMarin Pharmaceutical Inc. has announced that it has decided to pull the hemophilia A gene therapy ROCTAVIAN (valoctocogene roxaparvovec-rvox) from the United States market.

The National Bleeding Disorders Foundation (NBDF) mourns the passing of Lynn M. Malec, MD, MSc, a physician, researchers, and champion of the bleeding disorders community.

FY 2026 Funding Update  

Last week, the House of Representatives passed the final fiscal year (FY) 2026 appropriations bills. This includes the FY26 Labor, Health and Human Services appropriations bill, which provides funding for the federal health agencies. There were big wins in the bill for the bleeding disorders community, including:  

FY 2026 Funding Update  

Last week, the House of Representatives passed the final fiscal year (FY) 2026 appropriations bills. This includes the FY26 Labor, Health and Human Services appropriations bill, which provides funding for the federal health agencies. There were big wins in the bill for the bleeding disorders community, including:  

The National Bleeding Disorders Foundation (NBDF) is launching Educate to Elevate, a multi-year initiative to raise public awareness, educate communities, and improve healthcare access for individuals with bleeding disorders. 

The campaign features celebrity advocates including Melora Hardin, Amy Jo Johnson, Jonathan Frakes, Jason Ritter, and Greg Grunberg, alongside medical experts and people living with bleeding disorders, amplifying the experiences and challenges faced by people who live with these disorders every day.

Why This Matters

The National Bleeding Disorders Foundation (NBDF) offers multiple funding opportunities for bleeding disorders researchers across all career stages and disciplines. Through the Judith Graham Pool Postdoctoral Research Fellowships, the Sanofi-sponsored Career Development Award, the Takeda-sponsored Clinical Fellowship, and the Excellence Fellowships, NBDF’s grant programs support diverse research needs, including basic science, clinical projects, and innovative technologies.

After decades of research during which gene therapy was considered a distant goal, FDA-approved gene therapy options for hemophilia are now available in the United States. As these therapies enter real-world clinical practice, patients and care teams are navigating new access and coverage considerations that differ from more traditional treatment models.

The National Bleeding Disorders Foundation (NBDF) has announced the recipients of its 2025 research grant cycle, providing new research funding through its the Judith Graham Pool Postdoctoral Research Fellowship,  Excellence Fellowships in Social Work, Nursing, and Physical Therapy, and the Sanofi-sponsored Career Development Award. This year’s cohort reflects the full breath of bleeding disorders research, spanning basic science, clinical investigation, and qualitative studies led by nursing, social work, and physical therapy professionals.

Federal Updates: 

House of Representatives Reintroduces HELP Copays Act 

The National Bleeding Disorders Foundation (NBDF) has joined with World Federation of Hemophilia (WFH) with issuing a joint statement on a severe adverse event with marstacimab rebalancing agent for hemophilia (Hympavzi®). NBDF believes it is important for the community to be informed as quickly and thoroughly as possible about all adverse events that can impact people’s informed decision-making regarding their treatment. As Pfizer shares more information regarding their ongoing investigation into this event, NBDF will continue to update the community.

The National Bleeding Disorders Foundation (NBDF) is delighted to announce that Luke Luckey of Manchester, Michigan, was selected as the recipient of the 2025 Kevin Child Scholarship (KCS). The Child family selected Luke as this year’s KCS award recipient from among more than 20 applicants.

Hemab Therapeutics recently announced positive results from a Phase 2 clinical study of their investigational subcutaneous therapy sutacimig. 

Sutacimig is a laboratory-engineered bispecific antibody being developed as the first-ever prophylactic treatment for individuals with Glanzmann thrombasthenia (GT), one of several diseases the company is looking to ultimately target with this investigational, sub-Q therapy. 

On December 4, 2025, Representatives Kean (R-NJ), Barragán (DCA), Miller-Meeks (R-IA), Auchincloss (D-MA), Fitzpatrick (R-PA), and Watson-Coleman (DNJ) reintroduced the Help Ensure Lower Patient (HELP) Copays Act to make necessary and life-saving prescription medications more affordable for patients with rare, serious, and chronic conditions such as hemophilia, von Willebrand disease, and other rare bleeding disorders.

CSL recently announced the publication of five years’ worth of data from their HOPE-B clinical trial program, which has been investigating the company’s hemophilia B gene therapy Hemgenix® (etranacogene dezaparvovec).

Federal:

Fiscal Year 2026 Funding Update 

Star Therapeutics recently announced interim data from an ongoing phase 1/2 clinical trial evaluating its investigational von Willebrand disease (VWD) therapy VGA039. 

NBDF is excited to announce that its Facts About Inhibitors booklet is now available in an Arabic language version. Using easy-to-understand language, this publication includes important information about how inhibitors develop in people with hemophilia, key risk factors, and tips on getting screened.

The holiday season is a great time to recognize the many dedicated caregivers in the bleeding disorders community. This edition of the Resource Roundup (RR) includes resources that address everyday challenges universal to all caregivers as well as those unique to individuals with bleeding disorders. 

NBDF’s inaugural Research Roundtable was held in Washington, D.C. on October 15-16, 2025. The meeting brought together lived experience experts (LEEs), researchers, healthcare providers, and industry leaders in a pre-competitive, product-agnostic setting to address barriers faced by women, girls, and people with the potential to menstruate in bleeding disorders research. Although the FDA could not attend due to the government shutdown, NBDF engaged with them on key agenda topics beforehand and plans to resume the dialog with them further once the government reopens.

The World Federation of Hemophilia (WFH) recently published an Arabic language version of their booklet Women and Girls with Hemophilia (2023) which is meant to aid outreach and educational efforts around the world, especially for such a classically underserved subgroup. Historically, women and girls affected by hemophilia have experienced protracted delays in securing an accurate diagnosis and care that takes bleeding disorders into full account.